| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/25/2022 | 38.42% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
| 05/16/2022 | 49.06% | Piper Sandler | $85 → $70 | Maintains | Overweight |
| 01/25/2022 | 166.18% | Oppenheimer | $141 → $125 | Maintains | Outperform |
| 08/10/2021 | 38.42% | Credit Suisse | $55 → $65 | Maintains | Underperform |
| 03/05/2021 | 198.13% | Piper Sandler | $135 → $140 | Maintains | Overweight |
| 02/01/2021 | 176.83% | Oppenheimer | $75 → $130 | Maintains | Outperform |
| 01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
| 11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/25/2020 | -10.56% | Credit Suisse | $13 → $42 | Maintains | Neutral |
| 08/20/2020 | 59.71% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
| 07/27/2020 | -33.99% | Piper Sandler | $21 → $31 | Maintains | Overweight |
| 06/17/2020 | -55.28% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 05/29/2020 | -57.41% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/05/2020 | -76.58% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 11/05/2019 | -73.81% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
| 04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 05/09/2018 | -89.35% | Credit Suisse | $6 → $5 | Maintains | Outperform |
| 03/01/2018 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 03/01/2018 | -87.22% | Credit Suisse | $6.5 → $6 | Maintains | Outperform |
| 11/07/2017 | -84.03% | Credit Suisse | $10 → $7.5 | Maintains | Outperform |
Fulgent Genetics Questions & Answers
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Credit Suisse on August 25, 2022. The analyst firm set a price target for $65.00 expecting FLGT to rise to within 12 months (a possible 38.42% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Credit Suisse, and Fulgent Genetics initiated their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on August 25, 2022 so you should expect the next rating to be made available sometime around August 25, 2023.
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a initiated with a price target of $0.00 to $65.00. The current price Fulgent Genetics (FLGT) is trading at is $46.96, which is within the analyst's predicted range.